UT-DOXY.ME
18.3.2020 09:02:12 CET | Business Wire | Press release
Doxy.me, a free, secure telemedicine solution, stands ready to meet increased demand for a simple, convenient way for healthcare providers to meet with their patients remotely, promising to improve the health care experience during this critical time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200318005165/en/
Most telemedicine software products require a lengthy sales cycle, including training, legal review, and software or hardware to install. The process can take weeks to months to get up and running. Doxy.me was designed to be easy to install and simple to use; there are no downloads or apps to install and patients don't need to create accounts. The process is automated, so providers can start practicing telemedicine quickly, even within minutes. This approach means that Doxy.me is perfectly suited to handle the urgent demand for a telemedicine solution during the coronavirus outbreak.
“We’ve seen our sign-ups skyrocket over the past week, and we expect those numbers to keep doubling every day. We’re thrilled that we are in a position to make a difference in the world through our technology,” said Brandon Welch, Founder, Doxy.me. “We believe everyone should have access to telemedicine, and our focus is on assisting the providers and professionals trying to keep people safe and healthy.”
By incorporating standard clinical workflows such as patient check-in and waiting room into the design of Doxy.me, healthcare providers and their patients experience a familiar and natural visit. All the patient needs to start a telemedicine visit is a web link to the doctor’s Doxy.me room using a standard computer.
“Doxy.me brokers an encrypted peer-to-peer connection between a provider and the patient, meaning our server infrastructure won't become overburdened with high video load usage. This means we can scale indefinitely and can provide a free solution to healthcare providers,” said Dylan Turner, COO, Doxy.me.
“Doxy.me is easy to set up, easy to use, and the pricing option is transparent. This means that my busy private-practice office can triage possible coronavirus cases and see patents who are afraid to come in. I was able to set up and implement a telemedicine option overnight,” said Jessica Baker, Baker Family Medical Associates.
About Doxy.me
Founded by Brandon Welch, MS, PhD, and based in Salt Lake City, Utah and Charleston, South Carolina, Doxy.me is making it easier and more affordable for healthcare providers to care for their patients anywhere, including rural and underserved areas. Doxy.me provides patients with a virtual clinic experience that is strongly reminiscent of the traditional consultative model. The company uses state-of-the-art security and encryption protocols, making Doxy.me compliant with HIPAA, GDPR, PHIPA and HITECH requirements, and works on mobile devices (Safari/Chrome) and most desktop browsers. The company also offers a licensed version of Doxy.me for additional features or custom branding.
For more information about Doxy.me or telemedicine, see Doxy.me .
For more information about COVID-19, see the World Health Organization .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005165/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angel Aligner Unveils Six Innovations for 202711.11.2026 17:23:00 CET | Press release
Angel Elevates the Orthodontic Specialty by Focusing on Complex-Case Solutions Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bind
Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 15:58:00 CET | Press release
Partnerships span drug discovery, clinical research, preventive and reproductive health Launch of an AI Clinician Framework and a Trusted Research Environment for health and genomic data Four whitepapers address genomics, therapeutics, fertility and wearable technologies New programmes support health innovators and entrepreneurs More than 17,300 visitors from 85 countries, with 130 speakers across 45 sessions Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gath
De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 15:58:00 CET | Press release
The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par
Starr Chile Assigned A Rating from AM Best11.11.2026 14:30:00 CET | Press release
Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr
Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 14:22:00 CET | Press release
Southern California-Based Company has developed a disruptive biosensor for integration into next-generation screening and diagnostic devices Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom